

Financial news for AMRI dated on 2017-08-29: Notable Block Trades In Albany Molecular Research; 1M Shares At \$21.73 Followed By 250K Shares At \$21.73

Financial news for AMRI dated on 2017-08-18: 15 Biggest Mid-Day Gainers For Friday

Financial news for AMRI dated on 2017-08-18: 20 Stocks Moving In Friday's Pre-Market Session

Financial news for AMRI dated on 2017-08-17: S&P Dow Jones Indices Reports 'Control4 will replace Albany Molecular Research in the S&P SmallCap 600 effective prior to the open on Tues., Aug. 22'

Financial news for AMRI dated on 2017-06-08: Benzinga's Top Upgrades, Downgrades For June 8, 2017

Financial news for AMRI dated on 2017-06-08: JP Morgan Downgrades Albany Molecular Research to Neutral

Financial news for AMRI dated on 2017-06-07: Wall Street's M&A Chatter From June 6: Valeant-Bausch & Lomb, Albany Molecular, Horizon Pharma

Financial news for AMRI dated on 2017-06-06: 18 Biggest Mid-Day Gainers For Tuesday

Financial news for AMRI dated on 2017-06-06: 22 Stocks Moving In Tuesday's Pre-Market Session

Financial news for AMRI dated on 2017-06-06: Albany Molecular Research Shares to Resume Trade at 8 a.m. EDT

Financial news for AMRI dated on 2017-06-06: Albany Molecular Research Reports Will Be Purchased by The Carlyle Group, GTCR for \$21.75/Share in Cash

Financial news for AMRI dated on 2017-06-06: Albany Molecular Research Halted News Pending

Financial news for AMRI dated on 2017-06-06: Wall Street's M&A Chatter From June 5: YipTV-MagicJack, Verizon-Pandora, Albany Molecular, Rite Aid

Financial news for AMRI dated on 2017-06-05: Albany Molecular Research Shares Resuem, Pullback from Session Highs, Now Up 4%

Financial news for AMRI dated on 2017-06-05: Albany Molecular Research Shares to Resume Trade at 2:01:10 p.m. EDT

Financial news for AMRI dated on 2017-06-05: Albany Molecular Research Shares Spike Into Positive Territory, Now up 10%, Halted on Circuit Breaker Following Report Consortium, Carlyle In Talks to Buy Co.

Financial news for AMRI dated on 2017-05-11: The Market In 5 Minutes

Financial news for AMRI dated on 2017-05-11: Morgan Stanley Downgrades Albany Molecular Research To Equal-Weight

Financial news for AMRI dated on 2017-05-09: AMRI Sees FY17 Sales \$710-\$740M vs \$720M Est., Adj. EPS \$1.08-\$1.20 vs \$1.16 Est.

Financial news for AMRI dated on 2017-05-09: AMRI Reports Q1 Adj. EPS \$0.13 vs \$0.12 Est., Sales \$163.8M vs \$161M Est.

Financial news for AMRI dated on 2017-05-09: AMRI Sees FY17 Adj. EPS \$1.08-\$1.20 vs \$1.16 Est., Sales \$710M-\$740M vs \$720.5M Est.

Financial news for AMRI dated on 2017-05-09: AMRI Reports Q1 Adj. EPS \$0.13 vs \$0.12 Est., Sales \$163.8M vs \$161.5M Est.

Financial news for AMRI dated on 2017-05-02: AMRI Reports Received NIH Contract Win for Drug Substance Development, Manufacturing Services, No Terms Disclosed

Financial news for AMRI dated on 2017-04-24: Denovo Biopharma Reports Obtained Exclusive License to Albany Molecular Research's DB104

Financial news for AMRI dated on 2017-04-07: 12 Biggest Mid-Day Gainers For Friday

Financial news for AMRI dated on 2017-02-21: 15 Biggest Mid-Day Losers For Tuesday

Financial news for AMRI dated on 2017-02-21: AMRI Q4 EPS \$0.34 vs \$0.48 Est, Revenue \$191.3M vs \$221.3M Est

Financial news for AMRI dated on 2017-02-07: AMRI Reports Strategic Alliance to

## Advance Mass Spectrometry Capabilities for Drug Discovery

Financial news for AMRI dated on 2016-12-22: Albany Molecular Research Reports Sodium Nitroprusside Injection was Launched Following FDA Approval on December 8, 2016

Financial news for AMRI dated on 2016-11-29: AMRI Announces Multi-Year API Supply Agreement with Shire

Financial news for AMRI dated on 2016-11-08: AMRI Sees FY16 Sales \$590M-\$615M, Adj. EPS \$1.03-\$1.11

Financial news for AMRI dated on 2016-11-08: AMRI Reports Q3 Adj. EPS \$0.17, Adj. EBITDA \$25.5M, Contract Sales \$152.7M vs \$104.6M in Same Qtr. Last Year

Financial news for AMRI dated on 2016-09-30: Money Map Press Releases New Buy Recommendation For Albany Molecular Research

Financial news for AMRI dated on 2016-09-23: S-3 from Albany Molecular Research Shows Registration for ~7.05M Shares of Common Stock by Selling Holders

Financial news for AMRI dated on 2016-08-29: Albany Molecular Research To Reduce Workforce And Incur One-Time Charge Of \$5.7-\$7.3M

Financial news for AMRI dated on 2016-08-23: AMRI Reports Licensing of CRISPR-Cas9 Gene Editing Technology

Financial news for AMRI dated on 2016-08-04: AMRI Reports Q2 Adj. EPS \$0.36 vs \$0.32 Est., Adj. EBITDA \$26.8M, Sales \$120.8M vs \$123M Est.

Financial news for AMRI dated on 2016-07-18: Lauro Cinquantasette Reports 16.49% Stake in Albany Molecular Research in 13D

Financial news for AMRI dated on 2016-05-16: CEO Marth Buys 12,500 Shares of Albany Molecular Research @\$12.86/Share -Form 4

Financial news for AMRI dated on 2016-05-10: AMRI Sees FY16 Rev. \$465-\$490M vs. Est. \$479M, EPS \$1.00-\$1.10 vs. Est. \$1.05

Financial news for AMRI dated on 2016-05-10: AMRI Reports Q1 EPS \$0.07 vs. Est. \$0.21, Rev. \$102.8M vs. Est. \$107.2M

Financial news for AMRI dated on 2016-05-05: UPDATE: AMRI to Issue 7M Shares, Seller Note of \$63M, Remainder in Cash

Financial news for AMRI dated on 2016-05-05: AMRI to Acquire Euticals for \$358M in Cash, Stock Deal

Financial news for AMRI dated on 2016-02-17: Albany Molecular Sees FY16 Adj. EPS \$1-\$1.10 vs \$1.10 Est., Sales \$465M-\$490M vs \$508.6M Est.

Financial news for AMRI dated on 2016-02-17: Albany Molecular Research Reports Q4 Adj. EPS \$0.40 vs \$0.36 Est., Sales \$126.4M vs \$133M Est.

Financial news for AMRI dated on 2016-01-12: AMRI Announces 3-Year Extension of Insourcing Contract

Financial news for AMRI dated on 2016-01-11: Eagle Pharma and AMRI Announces Joint Development of Parental Drugs

Financial news for AMRI dated on 2016-01-07: Albany Molecular Research, Icagen Announce New Agreement That Combines Both Companies' Assets

Financial news for AMRI dated on 2016-01-07: AMRI, Icagen Ink Partnership Agreement To Provide Drug Discovery Customers With Ion Channel And Transporter Capabilities

Financial news for AMRI dated on 2015-12-10: AMRI, Multispan Ink Report Collaboration Deal

Financial news for AMRI dated on 2015-11-05: Albany Molecular Research Reports Q3 EPS \$0.14 Vs Est \$0.13; See 2015 Adj EPS \$0.90-\$0.95 vs Est \$0.92

Financial news for AMRI dated on 2015-09-15: AMRI Issues Update on FY15 Outlook Following Gadea Purchase; Sees Contract Sales \$386M-\$400M, Royalty Sales \$14M-\$16M, Adj. EBITDA \$75M-\$78M, Adj. EPS \$0.90-\$0.95 vs \$0.88 Est.

Financial news for AMRI dated on 2015-09-14: AMRI Names George Svokos COO

Financial news for AMRI dated on 2015-08-31: AMRI Announces Agreement with Saneca Pharmaceuticals, a.s. for Portfolio of Opium-Derived Active Pharmaceutical

## Ingredients

Financial news for AMRI dated on 2015-08-04: AMRI Reports Q2 EPS \$0.07, Sales \$89.5M, no estimate, Sees FY 2015 Revs \$80M-\$90M

Financial news for AMRI dated on 2015-07-16: AMRI Reports Purchase of Gadea Pharma Group for ~\$174M

Financial news for AMRI dated on 2015-06-01: Albany Molecular Research Reports Deal with HarkerBIO for Buffalo, NY, No Terms Disclosed

Financial news for AMRI dated on 2015-05-05: Albany Molecular Research Reports Q1 EPS Loss \$0.07 Vs Est \$0.015, May Not Compare, Sees FY Adj EPS \$0.80-\$0.90, Sees FY Contract Revs \$335M-\$370M

Financial news for AMRI dated on 2015-03-05: Albany Molecular Research Spikes to High on Volume

Financial news for AMRI dated on 2015-02-13: Guidance Uncertainty Resolved At Albany Molecular Research, 2015 Margin Expansion Now In Focus

Financial news for AMRI dated on 2015-02-12: AMRI Realigns Global Operations

Financial news for AMRI dated on 2015-02-12: Albany Molecular Research Reports Q4 EPS \$0.28 Vs Est \$0.33, Sales \$86.6M Vs Est \$91.90M

Financial news for AMRI dated on 2015-02-09: AMRI Names Jimmy Wang Chief Info Officer

Financial news for AMRI dated on 2015-02-09: AMRI Hires Jimmy Wang As Chief Information Officer

Financial news for AMRI dated on 2015-01-12: AMRI Announces Development Partnership with Genovi Pharma

Financial news for AMRI dated on 2015-01-09: Amri Announces Acquisition of Aptuit & Aseptic For \$60M

Financial news for AMRI dated on 2014-12-18: From 13G: Permian Increases Stake In Albany Molecular From 4.17% To 5.5% Passive Stake

Financial news for AMRI dated on 2014-12-18: First Analysis Initiates Coverage on Albany Molecular Research at Equal-weight

Financial news for AMRI dated on 2014-11-19: AMRI Announces Albuquerque, N.M. Manufacturing Facility Fully Operational

Financial news for AMRI dated on 2014-11-05: Midday Losers From November 5: Chuy's, Liberty Media, Zulily, Nu Skin

Financial news for AMRI dated on 2014-11-05: Mid-Day Market Update: Nu Skin Dips On Weak Forecast; EOG Resources Shares Jump

Financial news for AMRI dated on 2014-11-05: Mid-Morning Market Update: Markets Open Higher; Time Warner Earnings Top Estimates

Financial news for AMRI dated on 2014-11-05: Morning Market Losers

Financial news for AMRI dated on 2014-11-05: Albany Molecular Research, Inc. Reports Q3 EPS of \$(0.02), Down 115% YOY; Revenue of \$62.47M vs \$71.0M Est

Financial news for AMRI dated on 2014-09-09: Benzinga's Top Initiations

Financial news for AMRI dated on 2014-09-09: UPDATE: J.P. Morgan Initiates Coverage On Albany Molecular Research, Inc. As Increasingly Relevant Competitor

Financial news for AMRI dated on 2014-09-09: JP Morgan Initiates Albany Molecular Research At Overweight

Financial news for AMRI dated on 2014-09-09: JP Morgan Initiates Coverage on Albany Molecular Research, Inc. at Overweight, Announces \$25.00 PT

Financial news for AMRI dated on 2014-08-05: Albany Molecular Research, Inc. Sees FY2014 EPS \$0.87-0.92 vs \$0.92 Est

Financial news for AMRI dated on 2014-08-05: Albany Molecular Research, Inc. Reports Q2 EPS of \$0.22 vs \$0.20 Est; Revenue of \$68.18M vs \$65.64M Est

Financial news for AMRI dated on 2014-07-07: UPDATE: Sterne Agee Reiterates On Albany Molecular Research On Raised Estimates

Financial news for AMRI dated on 2014-07-01: AMRI Closes Purchase of Oso Biopharma Manufacturing, Expecting Deal to Add to Adj. EPS

Financial news for AMRI dated on 2014-06-16: UPDATE: Morgan Stanley Reiterates On Albany Molecular Research Ahead Of Conference Call

Financial news for AMRI dated on 2014-06-11: UPDATE: Morgan Stanley Reiterates On Albany Molecular Research On Model/Valuation Update

Financial news for AMRI dated on 2014-06-02: UPDATE: AMRI Expecting Deal to Add to 2014 Earnings

Financial news for AMRI dated on 2014-06-02: AMRI Announces Will Buy Oso Biopharma Manufacturing for \$110M in Cash

Financial news for AMRI dated on 2014-05-16: Albany Molecular Research VP Svokos Buys 10,000 Shares @\$15.60/Share -Form 4

Financial news for AMRI dated on 2014-05-13: Albany Molecular Research CEO Marth Buys 30,000 Shares @\$15.40/Share -Form 4

Financial news for AMRI dated on 2014-05-06: Albany Molecular Research, Inc. Reports Q1 EPS of \$0.16 vs \$0.23 Est; Revenue of \$59.30M vs \$62.19M Est

Financial news for AMRI dated on 2014-04-16: AMRI Announces Realignment of Discovery, Development Services, Will End Operations in Syracuse, NY by End of June, Sees One-Time Charges \$5.75-6.5M

Financial news for AMRI dated on 2014-04-09: Mid-Afternoon Market Update: Markets Post a Large Rally as Intuitive Surgical Shares Remain Down

Financial news for AMRI dated on 2014-04-09: Mid-Day Market Update: Alcoa Surges On Upbeat Earnings; Intuitive Surgical Shares Slip

Financial news for AMRI dated on 2014-04-09: Mid-Morning Market Update: Markets Open Higher; Constellation Brands Profit Beats Street View

Financial news for AMRI dated on 2014-04-09: Morgan Stanley Initiates Coverage on Albany Molecular Research, Inc. at Overweight, Announces \$19.00 PT

Financial news for AMRI dated on 2014-04-07: Stocks To Watch For April 7, 2014

Financial news for AMRI dated on 2014-04-04: UPDATE: AMRI Expecting Deal to Add \$0.06-0.07/Share to Profit in FY14

Financial news for AMRI dated on 2014-04-04: AMRI Completes Acquisition of Cedarburg Pharmaceuticals, Inc

Financial news for AMRI dated on 2014-03-26: Fabrinet, Albany Molecular Research to Join S&P SmallCap 600

Financial news for AMRI dated on 2014-03-24: US Stock Futures Up Ahead Of Manufacturing PMI

Financial news for AMRI dated on 2014-03-24: UPDATE: AMRI to Acquire Cedarburg Pharmaceuticals for \$28.2M in Cash

Financial news for AMRI dated on 2014-03-24: AMRI To Acquire Cedarburg Pharmaceuticals

Financial news for AMRI dated on 2014-03-21: Mid-Day Market Update: Nike Drops On Cautious Forecast; Endocyte Shares Spike Higher

Financial news for AMRI dated on 2014-02-12: Albany Molecular Research, Inc. Sees FY2014 EPS \$0.72-0.80 vs \$0.69 Est

Financial news for AMRI dated on 2014-02-12: Albany Molecular Research, Inc. Reports Q4 EPS of \$0.22 vs \$0.17 Est; Revenue of \$67.12M vs \$68.09M Est

Financial news for AMRI dated on 2013-12-03: Benzinga's Top Downgrades

Financial news for AMRI dated on 2013-12-03: UPDATE: Sterne Agee Downgrades Albany Molecular Research on Less Optimism in Core Business Value

Financial news for AMRI dated on 2013-12-03: Sterne Agee Downgrades Albany Molecular Research, Inc. to Neutral, Lowers PT to \$12.00

Financial news for AMRI dated on 2013-11-06: Albany Molecular Research, Inc. Raises

FY2013 EPS Guidance from \$0.54-0.65 to \$0.60-0.67 vs \$0.64 Est

Financial news for AMRI dated on 2013-11-06: Albany Molecular Research, Inc. Reports Q3 EPS of \$0.13 vs \$0.11 Est; Revenue of \$60.80M vs \$62.11M Est

Financial news for AMRI dated on 2013-09-30: AMRI Wins Development, Manufacture Contract from the UK Gov't, Provides Up to \$43M in Funding

Financial news for AMRI dated on 2013-09-09: AMRI Names William S. Marth as President and CEO

Financial news for AMRI dated on 2013-08-19: Stocks to Watch for August 19, 2013

Financial news for AMRI dated on 2013-08-13: Stocks to Watch for August 13, 2013

Financial news for AMRI dated on 2013-08-12: UPDATE: Albany Molecular Shares Bounce Back Towards \$11 Level, Fail Near 38.2% Retracement Of \$12.81-9.82 Move

Financial news for AMRI dated on 2013-08-12: UPDATE: Albany Molecular Research Shares Down Roughly 20% At \$10.27, Fell As Much As 23.3% At Low On Disclosure That Bristol-Myers Squibb Has Canceled Development of Drug With Company

Financial news for AMRI dated on 2013-08-12: Albany Molecular Files Form 8-K Disclosing Termination Of Development Of BMS-820836 With Bristol-Myers Squibb

Financial news for AMRI dated on 2013-08-06: Albany Molecular Research, Inc. Sees Q3 EPS \$0.09-0.12 vs \$0.10 Est, Sees Sales \$51.0M-53.0M vs \$57.50M Est; Narrows FY13 Adj. EPS from \$0.52-0.65 to \$0.54-0.65, Sales from \$205-213M to \$209-213M

Financial news for AMRI dated on 2013-08-06: Albany Molecular Reports Q2 Adj. EPS \$0.12 on Sales \$59.3M; Sees Q3 Adj. EPS \$0.08-0.12 on Sales \$51-53M, Raises FY13 Adj. EPS Guidance from \$0.52-0.65 to \$0.54-0.65, Sales from \$205-213M to \$209-213M

Financial news for AMRI dated on 2013-07-22: FDA Performs Re-inspection of AMRI Burlington MA Facility

Financial news for AMRI dated on 2013-06-12: Afternoon Market Gainers

Financial news for AMRI dated on 2013-06-12: UPDATE: Sterne Agee Resumes Coverage on Albany Molecular Research at Buy on Good Market Position

Financial news for AMRI dated on 2013-06-11: Sterne Agee Initiates Coverage on Albany Molecular Research, Inc. at Buy, Announces \$15.00 PT

Financial news for AMRI dated on 2013-06-05: AMRI Announces Appointment of William Marth as Chairman of the Board of Directors

Financial news for AMRI dated on 2013-05-07: Albany Molecular Research, Inc. Reports Q1 EPS of \$0.23; Revenue of \$59.51M

Financial news for AMRI dated on 2013-03-06: UPDATE: Sterne Agee Raises PT on Albany Molecular Research on Raised Estimates

Financial news for AMRI dated on 2013-03-05: Sterne Agee Maintains Buy on Albany Molecular Research, Inc., Raises PT to \$12.00

Financial news for AMRI dated on 2013-02-12: Albany Molecular Research, Inc. Reports Q4 EPS of \$0.17 vs \$0.09 Est; Revenue of \$67.20M vs \$56.49M Est

Financial news for AMRI dated on 2013-02-11: A Peek Into The Market Before The Trading Starts

Financial news for AMRI dated on 2013-02-11: AMRI Announces Deal for Exclusive Rights to Tubulin Inhibitor Program for Cancer

Financial news for AMRI dated on 2013-01-08: AMRI Names Saffee VP of Large Scale Manufacturing

Financial news for AMRI dated on 2012-11-30: AMRI Realigns Discovery Services to Support Customer Demand

Financial news for AMRI dated on 2012-11-20: Stocks Hitting 52-Week Highs

Financial news for AMRI dated on 2012-11-06: Albany Molecular Boosts FY EPS Outlook from \$0.10-0.16 to \$0.16-0.20 vs \$0.12 Est

Financial news for AMRI dated on 2012-11-06: Albany Molecular Research Reports Q3 EPS \$0.00 vs \$-0.02 Est; Revenues \$55.8M vs \$50.80M Est

Financial news for AMRI dated on 2012-09-17: AMRI Announces Strategic Contract with Knopp Biosciences

Financial news for AMRI dated on 2012-08-01: Albany Molecular Research Reports Q2 EPS \$0.06 vs \$0.02 Est; Revenues \$50.01M vs \$52.00M Est

Financial news for AMRI dated on 2012-04-12: Albany Molecular Entered \$20M Credit Line

Financial news for AMRI dated on 2012-04-03: AMRI Signs Exclusive Option to License its Tubulin Inhibitor Program for Cancer

Financial news for AMRI dated on 2012-02-07: Albany Molecular Research Reports Q4 EPS \$(0.19) vs \$(0.12) Est; Revenues \$46.60M vs \$49.30M Est

Financial news for AMRI dated on 2011-12-05: Sterne Agee Maintains Buy, \$7 PT on Albany Molecular Research

Financial news for AMRI dated on 2011-11-14: Sterne Agee Initiates Albany Molecular Coverage: Buy, \$7 PT

Financial news for AMRI dated on 2011-11-08: Albany Molecular Reports Q3 Revenues \$50.20M vs \$53.36M Est

Financial news for AMRI dated on 2011-09-26: AMRI Receives FDA Notification on Proposed Corrective Actions

Financial news for AMRI dated on 2011-08-18: AMRI Receives NIH Contract Award for the Development of Pre-Clinical Drug Candidates to Treat Diseases of the Nervous System

Financial news for AMRI dated on 2011-08-08: Albany Molecular Research Reports Q2 EPS \$(0.02) vs \$(0.03) Est; Revenues \$53.9M vs \$52.42M Est

Financial news for AMRI dated on 2011-06-28: AMRI and Proteros Biostructures GmbH Announce Strategic Alliance

Financial news for AMRI dated on 2011-05-25: AMRI to Receive Milestone Payment from Bristol-Myers Squibb for the Initiation of a Phase II Study

Financial news for AMRI dated on 2011-05-05: Jefferies Comments On Albany Molecular Rsrch Growth Focus

Financial news for AMRI dated on 2011-05-04: CEOWORLD Most Actives Top Healthcare stocks picks on 5/4/11- GENE, SPPI, AMRI, GTXI, AFFX,KV.A, SCLN, CBM, CERS, CEPH, TEVA, THC, JNJ

Financial news for AMRI dated on 2011-04-07: AMRI Announces Development and Commercial Supply Agreement with Parnell Manufacturing